NCT06520319 Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma
| NCT ID | NCT06520319 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | First Affiliated Hospital of Fujian Medical University |
| Condition | Medullary Thyroid Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2023-06-21 |
| Primary Completion | 2024-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 20 participants in total. It began in 2023-06-21 with a primary completion date of 2024-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cholecystokinin-2 (CCK2) receptor is overexpressed in more than 90% of MTC cases, and preclinical studies have shown that 68Ga-MGS5 (targeting CCK2) has good stability in vivo and is promising for diagnosis and staging of MTC. This prospective study will compare the diagnostic effects of 68Ga-MGS5 and 68Ga-DOTATATE on MTC primary foci, lymph node metastasis, and distant metastasis, and explore the effect of 68Ga-MGS5 PET/CT on the clinical staging (TNM staging) of MTC.
Eligibility Criteria
Inclusion Criteria: * Patients of either gender, aged ≥ 18 years and ≤80 years. * Patients with pathologic findings confirming the diagnosis of MTC * Patients with MTC recurrence * Signed written consent Exclusion Criteria: * Pregnant or breastfeeding female patients * Patients with claustrophobic behavior * The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent
Contact & Investigator
Weibing Miao
PRINCIPAL INVESTIGATOR
First Affiliated Hospital of Fujian Medical University
Frequently Asked Questions
Who can join the NCT06520319 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Medullary Thyroid Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06520319 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06520319 currently recruiting?
Yes, NCT06520319 is actively recruiting participants. Contact the research team at miaoweibing@126.com for enrollment information.
Where is the NCT06520319 trial being conducted?
This trial is being conducted at Fuzhou, China.
Who is sponsoring the NCT06520319 clinical trial?
NCT06520319 is sponsored by First Affiliated Hospital of Fujian Medical University. The principal investigator is Weibing Miao at First Affiliated Hospital of Fujian Medical University. The trial plans to enroll 20 participants.